Adherence to diabetes treatments falls after a cancer diagnosis

Adherence to glucose lowering therapies in diabetes patients falls following a cancer diagnosis, new research finds

Patients with both cancer and diabetes have a higher overall mortality rate than patients with a cancer diagnosis alone. So researchers wondered whether a cancer diagnosis affects patient’s adherence to glucose-lowering drugs[1]

They measured the ‘medication possession ratio’ (MPR), by tracking when and how frequently patients refilled their medications, for 3,281 diabetic patients with cancer and 12,891 diabetic patients without cancer. Before a cancer diagnosis, the MPR increased monthly by 0.1% but dropped significantly by 6.3% at diagnosis and continued to fall monthly by 0.2%.

The findings confirm that adherence to glucose-lowering therapies in diabetes patients falls following a cancer diagnosis — but further research is needed to find out why.



[1] Zanders MMJ, Haak HR, van Herk-Sukel MPPetal.Impactof canceron adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia 2015. doi: 10.1007/s00125-015-3497-8.

Last updated
The Pharmaceutical Journal, PJ, 7 February 2015, Vol 294, No 7848;294(7848):DOI:10.1211/PJ.2015.20067755

You may also be interested in